Michal Eisenbach-Schwartz,Kuti Baruch,Neta Rosenzweig
申请号：
US15212231
公开号：
US20160319021A1
申请日:
2016.07.16
申请国别(地区):
US
年份:
2016
代理人:
摘要：
A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
